Aurobindo reduces losses following three US FDA observations

After the business got three observations from the US Food and Drug Administration (USFDA), Aurobindo Pharma shares recovered their initial losses and fluctuated somewhat.

Following an examination of Aurobindo Pharma's Unit III, a formulation manufacturing plant located in Bachupally Village in Telangana's Medchal Malkajgiri district, from July 14 to 21, the US FDA issued the Form 483 with three observations.

The company stated in a statement, "The observations are procedural in nature and we will respond to the USFDA within the stipulated timelines and work closely with USFDA to close the observations at the earliest." 

Additionally, from May 15 to 19, the USFDA performed an examination at the business' Unit XIV at Jawaharlal Nehru Pharma City in the Anakapalli area of Andhra Pradesh. The facility was classified as having suggested voluntary action (VAI) in the establishment inspection report, the business reported on July 17. 

Sevelamer Hydrochloride Tablets 400mg and 800mg, which are intended to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Renagel Tablets, 400mg and 800mg, of Genzyme Corporation, were given their final approval to be manufactured and marketed by Aurobindo Pharma's wholly owned subsidiary APL Healthcare on July 12.

Source: Media Reports

Top stories
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read . 02 Aug 2024 . 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read . 02 Aug 2024 . 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read . 02 Aug 2024 . 12:36 PM

Related Blogs
blog-logo

Share Market

blog-logo

9 mins read . 30 Oct 2024

Top Small Finance Bank Stocks in India

  • 0 people read
blog-logo

Insights

blog-logo

10 mins read . 30 Oct 2024

How to do Valuation Analysis of a Company

  • 0 people read
Kickstart your equities journey today You've got this
By submitting this I agree to the terms & conditions